{
  "ticker": "TRU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958527",
  "id": "02958527",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krwlcpd037fv.pdf",
  "summary": "### **Key Market Update Summary (TruScreen Group Limited \u2013 ASX/NZX: TRU)**  \n\n- **Uzbekistan:** Regulatory approval received; validation program to begin in Tashkent as precursor to national screening program (11M+ women eligible).  \n- **Zimbabwe:** Re-validation by Ministry of Health (7\u201321 July 2025), enabling program expansion beyond Masvingo Province.  \n- **Vietnam:** Ho Chi Minh City screening program (260K women over 5 years) starting **28 July 2025**; staff trained and devices shipped.  \n- **India:** First commercial order secured (10 devices + 1,080 sensors from Renovate Biologicals).  \n- **Clinical Validation:** Peer-reviewed Beijing study confirms TruScreen\u2019s superiority as standalone screening tool (86.4% sensitivity, 74.4% specificity for CIN II+ lesions).  \n\n**Strategic Implication:** Progress aligns with emerging market expansion (China, India, Indonesia) and reinforces technology adoption pipeline. No capital raising or financial data disclosed.  \n\n*Rules followed: Excluded operational/executive commentary; focused on jurisdiction-specific catalysts and clinical validation impact.*",
  "usage": {
    "prompt_tokens": 2578,
    "completion_tokens": 242,
    "total_tokens": 2820,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:44:56.152501"
}